Summary

Location
at San Francisco, California and other locations
Dates
study started
Principal Investigator
by Robert E. Goldsby
Headshot of Robert E. Goldsby
Robert E. Goldsby

Description

Summary

This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in Children's Oncology Group studies may allow doctors learn more about the long-term effects of cancer treatment and help them reduce problems related to treatment and improve patient quality of life.

Official Title

Umbrella Long-Term Follow-Up Protocol

Details

PRIMARY OBJECTIVES:

  1. To develop a mechanism for tracking and retaining patients enrolled on Children's Oncology Group (COG) protocols.

II. To maintain regular, lifetime contact with patients in order to obtain current identification and contact information, and self/parent-reported health status.

III. To locate patients who are lost-to-follow-up for COG (or Legacy Group) protocols targeted for follow-up by the Long-Term Follow-Up Center (LTFC).

IV. To provide current patient contact information and self/parent-reported health status updates to the COG Statistics and Data Center (SDC) and to each patient's COG institution.

  1. To facilitate collection of protocol-specific outcome data through collaboration with the LTFC Oversight Committee, the SDC, and the member institutions.

OUTLINE: This is an umbrella protocol for all long-term follow-up at COG institutions.

Within 3 months of enrollment on ALTE05N1, patients receive a mailed packet introducing the Long-Term Follow-Up Center (LTFC). Patients are asked to complete a patient response form, verify information provided in packet, and update contact and health status information. The Health Status Update Form is a brief document including questions about current health status, disease status, and cancer therapy received since the last mailing. Patients may respond by use of postage prepaid envelopes, email, or 24-hour toll-free telephone number.

Keywords

Acute Lymphoblastic Leukemia, Brain Neoplasm, Hematopoietic Cell Transplantation Recipient, Hodgkin Lymphoma, Osteosarcoma, Rhabdomyosarcoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Brain Neoplasms, Assessment of Therapy Complications

Eligibility

Inclusion Criteria:

  • The patient must reside in the U.S. on the date of enrollment to ALTE05N1
  • All patients and/or their parents or legal guardians must sign a written informed consent
  • All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met

Locations

  • UCSF Medical Center-Parnassus in progress, not accepting new patients
    San Francisco California 94143 United States
  • UCSF Medical Center-Mission Bay accepting new patients
    San Francisco California 94158 United States
  • Kaiser Permanente-Oakland accepting new patients
    Oakland California 94611 United States
  • Valley Children's Hospital accepting new patients
    Madera California 93636 United States
  • Lucile Packard Children's Hospital Stanford University accepting new patients
    Palo Alto California 94304 United States

Lead Scientist at UCSF

  • Robert E. Goldsby
    Professor, Pediatrics, School of Medicine. Authored (or co-authored) 114 research publications

Details

Status
accepting new patients
Start Date
Sponsor
Children's Oncology Group
ID
NCT00736749
Study Type
Observational
Participants
Expecting 4738 study participants
Last Updated